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Abstract 
The lack of specificity in neuroimaging studies of neurological and psychiatric diseases 
suggests that these different diseases have more in common than is generally considered. 
Potentially, features that are secondary effects of different pathological processes may share 
common neurobiological underpinnings. Intriguingly, many of these mechanisms are also 
observed in studies of normal (i.e., non-pathological) brain ageing. Different brain diseases 
may be causing premature or accelerated ageing to the brain, an idea that is supported by 
a line of ‘brain ageing’ research that combines neuroimaging data with machine learning 
analysis. In reviewing this field, I conclude that such observations could have important 
implications, suggesting that we should shift experimental paradigm: away from 
characterising the average case-control brain differences resulting from a disease towards 
methods that place individuals in their age-appropriate context. This would also lead 
naturally to clinical applications, whereby neuroimaging could contribute to a personalised-
medicine approach to improve brain health. 
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1. Introduction 
Neuroimaging has provided myriad novel insights into the structure and function of the 
living human brain for well over two decades. The application of neuroimaging to 
neurological and psychiatric diseases (i.e., brain diseases) has generated swathes of 
information about the anatomical and functional changes associated with these disabling 
conditions. The canonical experimental paradigm compares a group of individuals meeting 
the disease’s diagnostic criteria with a group of healthy controls. Statistical analysis is then 
conducted on measures derived from neuroimaging data to ascertain which aspects of brain 
structure and function differ on average between the disease and control groups. However, 
there is a critical lack of specificity in these neuroimaging findings (Table 1), with similar 
findings appearing across a wide range of different diagnoses. These findings have been 
derived from various neuroimaging modalities, including T1-weighted magnetic resonance 
imaging (MRI), T2-FLAIR MRI, diffusion-MRI, functional-MRI, arterial spin labelling and 
fludeoxyglucose (18F) (FDG) positron emission tomography (PET). Data from these methods 
can be used to infer brain volumes, cortical thickness, white matter hyperintensity volume, 
white matter microstructure, functional connectivity, cerebral perfusion and cerebral 
metabolism. It is apparent when viewing the breadth of the neuroimaging literature that 
changes to these different aspects of brain structure and brain function can occur in many 
different contexts.  
The commonalities across diseases can be highlighted by taking two common brain diseases 
as examples. Alzheimer’s disease (AD) research has consistently documented lower grey 
matter and white matter volume,[1] cortical thinning,[2] lower fractional anisotropy (FA; 
reflecting white matter microstructure),[3] higher white matter hyperintensity load,[4] 
abnormal functional connectivity,[5] and reductions in cerebral perfusion[6] and 
metabolism.[7] While this valuable research has given considerable insights into the 
pathological processes involved in AD, this same pattern of brain changes has also been 
reported in Major Depressive Disorder (MDD).[8-13] Furthermore, going beyond these more 
general whole-brain changes, atrophy to the hippocampal region is commonly presented 
as being a characteristic hallmark of AD.[14, 15] Ideally, focusing on specific regions using the 
anatomical precision provided by high-resolution techniques would improve the specificity 
of neuroimaging measures. However, it is notable that hippocampal atrophy is also 
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commonly seen in MDD,[16] alongside a range of other conditions.[17-20] Hence distinguishing 
AD from MDD using neuroimaging is not straightforward, despite the differential clinical 
presentation and likely treatment implications. Clearly, AD and MDD are not the same 
disease, nor do they have the same pathogenesis. Nevertheless, there appears to be a 
substantial overlap in terms of changes to the brain. This is potentially due to the common 
comorbidity of depressive symptoms in people with AD,[21] which questions the validity of 
‘pure’ (i.e., comorbidity-free) experimental groups. Another issue is more statistical; the 
variability within each disease group is often overlooked, with the assumption of within-
group homogeneity implicitly included in experimental designs. The overlap between AD 
and MDD is just an example; the lack specificity between multiple pairwise combinations of 
diseases can be seen in Table 1.  
Neuroimaging’s lack of specificity has important consequences for research into brain 
diseases. Quantifying the parameters on which patients of a given brain disease differ from 
healthy people is insufficient to either definitively make diagnoses nor explain the symptoms 
associated with that disease. This fact has limited the application of neuroimaging in clinical 
contexts, and it is rare that insights from quantitative neuroimaging have resulted in patient 
benefit (pre-neurosurgical planning using diffusion-MRI is an exception). Given the 
increasingly high burden of brain diseases on our ageing society and the manifest potential 
of neuroimaging, these limitations to its clinical application need to be overcome.  
There are contrasting explanations behind this general lack of specificity in neuroimaging 
studies of brain diseases. The relatively small sample sizes generally used in neuroimaging, 
due to the financial and logistical challenges of expensive scanning studies, may be a 
contributor. Arguably, larger samples could lead to more precise localisation of 
neuroanatomical signatures, a concept that is supported by the results of activation 
likelihood estimation (ALE) meta-analyses.[22, 23] In theory, this should enable better 
separation between diseases; however, ALE meta-analyses have also highlighted 
neuroanatomical overlap between neuropsychiatric disorders.[24, 25] Greater numbers may in 
fact decrease specificity even further. Another potential explanation is the spatial resolution 
of neuroimaging methods, which is somewhat coarse relative to the size of brain cells (mm 
versus m). This may mean that present technology is insufficient to wholly discriminate 
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brain diseases and that the key distinguishing signatures are not yet visible. A third 
possibility is that the diagnostic process of brain diseases is flawed. This may well be the 
case in psychiatric diseases, where diagnosis is often imperfect and symptomatic overlap 
between diagnostic categories is pronounced.[26, 27] However, this is less likely to be true of 
neurological diseases, where the cause of pathology is often better understood. 
Here, I would like to propose an alternative explanation for the commonalities across 
diseases. Potentially, despite disparate aetiologies, these diseases could share common 
secondary neurobiological effects. These secondary effects, occurring downstream to the 
primary pathogenesis, result in changes detectable with neuroimaging, leading to the 
observed overlap in profiles of neuroimaging measures. Furthermore, these deleterious 
changes to the health of the brain can also be caused by the accumulation of subtle damage 
that may not manifest as a diagnosable disease. Such a build-up of minute damage is also 
observed in, and may well be the driver of, brain ageing. 
2. Changes in neuroimaging measures commonly observed in brain diseases are also seen in 
ageing 
Neuroimaging has been used frequently in the study of ageing.[28] Intriguingly, the patterns 
of age-associated changes detected using neuroimaging overlaps substantially with those 
observed in the brain diseases. Ageing in this context refers to ‘normal’ ageing. While 
this may well be a misnomer given the individual differences observed in brain ageing,[29] 
normal differs from ‘healthy’ in that normal refers to ageing in the absence of clinically-
diagnosed pathology, whether the individuals in question are particularly healthy or not. 
Research into the characteristics of the ageing brain have used the full gamut of biological 
techniques to assess changes at molecular, cellular, tissue and organ levels. Post-mortem 
research has associated older brains with decreased weight, larger ventricles and thinner 
cortices.[30-32] There is also evidence of the gradual breakdown of the blood-brain barrier 
during ageing, such as the accumulation of blood-derived proteins (e.g., albumin, 
fibrinogen).[33] Alongside this, retinal imaging studies have reported retinopathy and 
microvascular narrowing,[34, 35] suggesting that the cerebrovascular system deteriorates with 
increasing age. Histopathology has shown that axons degenerate, glial numbers change, 
synapses are pruned, and eventually neuronal loss occurs.[32, 36-38] Gene expression changes 
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in astrocytes and neurons, [39, 40] and the epigenetic signature of brain tissue changes, 
particularly DNA methylation at CpG sites across the genome.[41] Neuroimaging itself has 
provided many insights into brain ageing. MRI has shown reduced brain tissue volume, 
cortical thinning, leukoaraiosis (i.e., white matter hyperintensities on T2-weighted MRI), 
altered white matter microstructure, changes to structural and functional connectivity, 
reduced cerebral perfusion, microbleeds and greater blood-brain barrier permeability.[42-48] 
PET has been used to show reduced cerebral metabolism, the deposition of beta-amyloid 
and signs of neuroinflammation.[49-51] As can be seen in Table 1., these age-related changes 
to the brain also tally with those seen across multiple brain disorders. While the tabulated 
studies are a rather selective representation, with levels of evidence varying considerably, 
this overlapping pattern of findings supports both a lack of disease specificity and the 
absence of a clear distinction between ageing and disease when viewed through the lens of 
the neuroimaging literature. Even relatively uncommon techniques like dynamic contrast-
enhanced MRI, that have yet to be applied in psychiatric disorders, are likely to evince more 
commonalities, given evidence for the involvement of blood-brain barrier integrity in 
psychosis and related conditions.[52] 
3. Neurobiological commonalities are seen in ageing and disease 
Whether ageing itself is a disease or not is a highly contentious and controversial subject of 
debate. On one hand, authorities such as Hayflick,[53] contend that ageing is driven by 
fundamentally different processes to any known disease, while others assert that ageing is 
best understood as a pathology.[54] I support the conclusion proposed by Gladyshev and 
Gladyshev,[55] that: “aging is neither a disease, nor a non-disease.” In other words, the 
overlap between ageing and disease is sufficient that they should not be considered entirely 
separate entities, yet at the same time ageing does not fall neatly into commonly accepted 
definitions of disease. In particular, the ageing process does not necessarily require clinical 
intervention, at least for the majority of the lifespan. Nevertheless, ageing is the leading risk 
factor for many different diseases, and even when ageing is not a risk factor, ageing co-
occurs with all chronic diseases, by their very definition. However, from the perspective of 
brain ageing, I contend that arguments over whether or not ageing truly is a disease are 
somewhat academic. What is more important is that if common mechanisms can be 
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identified in different states, then it is reasonable to consider common therapies for treating 
those states if they are pathological or increase the risk of pathology. 
Alongside the neuroimaging commonalities outlined above, there also appear to be 
neurobiological commonalities across disease. Though different brain diseases are often 
defined and distinguished by contrasting aetiological and pathophysiological factors, there 
is evidence that suggests a range of common effects on the brain across disease states. For 
example, traumatic brain injury, AD, MDD and multiple sclerosis have all been linked to 
neuroinflammation, oxidative stress, a heightened immune response, mitochondrial 
dysfunction and epigenetic alterations.[56-65] As mentioned, these phenomena have also 
been associated with neurobiology of normal ageing.[41, 66-69] The neurobiological overlap 
between ageing and disease is paralleled outside the brain, with mechanistic commonalities 
observed in other bodily systems (see Franceschi and colleagues for review).[70] 
So how to reconcile these observed commonalities between ageing and disease? That 
diseases may differ only quantitatively from ageing, as measured by neuroimaging, is an 
important consideration. This view implies that brain diseases represent one end of a 
spectrum that also contains ‘healthy’ and ‘normal’ ageing. If true, this calls into 
question the common conception that diseases are qualitatively different from health. It also 
means that the lines drawn to distinguish disease and health, or between two diseases, are 
likely to be more or less arbitrary; casting into doubt the classic univariate case-control 
design used in biomedical research. 
Potentially, the fact that certain biological states lead to clinical pathology and others do 
not, may be more due to underlying individual differences rather than qualitative differences 
in neurobiological mechanisms. Thus, understanding how a patient’s biological state 
compares to the spectrum of similarly aged people provides an alternative and promising 
approach to putting chronic brain diseases properly in the context of ageing-related 
changes. One way of achieving this is to consider measurements of underlying biological 
ageing and how these can be affected in disease states. 
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4. Neuroimaging can be used to model brain ageing in health and disease 
4.1 Measuring underlying ‘biological age’, using neuroimaging  
Independently from neuroscience, the field of biogerontology has long sought to find 
measures of ‘biological age’, thought to represent the ‘true’ age of an individual more 
accurately than chronological age alone. There are a plethora of different approaches to 
measuring biological age, and the search for ageing biomarkers is gathering pace.[71] These 
ageing biomarkers are conventionally based on blood-derived or physiological measures, 
and measurements of brain ageing are seldom considered. However, neuroscientists have 
begun to adopt this biogerontological approach and methods for generating ageing 
biomarkers have been developed using neuroimaging data.[72, 73] 
The idea of generating a “brain-predicted age”, in other words a biological-age prediction 
derived using measurements of the brain (commonly structural neuroimaging), is becoming 
increasingly common.[74] This is thanks to the adoption of sophisticated machine learning 
methods for statistical analysis. These methods allow extremely high-dimensional datasets, 
such as those derived from MRI scans (with tens of thousands of voxels as data points), to 
be analysed in an efficient and principled manner. This development has been enabled by 
both the continual improvements in computing performance and the proliferation of 
publicly-available datasets, providing sufficiently large sample sizes for machine learning 
methods to generate accurate predictions. By learning the relationship between patterns of 
neuroimaging data and chronological age in groups of healthy people (i.e., the training set), 
a predictive model can be built whereby accurate estimations of chronological age can be 
made from data not used to train the model (i.e., the test set). Such models are able routinely 
to generate predictions with an accuracy of within five years of actual chronological in 
adults.[72, 73, 75, 76] 
4.2 What can ‘brain-predicted age’ tell us about how diseases interact with the ageing brain? 
In attempts to better understand the effects of diseases on the ageing brain, models of 
brain-predicted age have been applied in a range of different contexts. This includes a 
number of neurological conditions: Added brain ageing has been reported after a traumatic 
brain injury,[75] in people with treatment-resistant epilepsy,[77] and to a lesser extent, in older 
adults with HIV that is successfully treated with anti-retroviral therapy.[78] Cognitive 
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performance was assessed in these disease samples, showing moderate, but consistent 
relationships between brain-predicted age and neuropsychological test performance in 
both patients and controls. Individuals with older-appearing brains tended to perform worse 
across different cognitive domains and more globally. This is in line with behavioural studies 
that show that ageing is generally associated with declining cognitive performance.[79] 
A crucial next step for research using brain-predicted age will be to conduct longitudinal 
follow-up of clinical samples. This will help establish whether the apparent increases in brain 
ageing remain constant or whether the gap increases over time, suggesting an accelerating 
process. The distinction between a static and an accelerating process is crucial. This will tell 
us whether the disease processes are adding to those seen in normal ageing (i.e., the 
accumulation of more damage) or whether there is an interaction between disease-specific 
pathogenic factors and normal ageing processes. The latter scenario is likely to be 
deleterious as progressive damage will result in a more rapid onset of cognitive decline, 
other disease symptoms and in some cases, dementia. 
With regard to specific risk factors for dementia, brain-predicted ageing has been assessed 
in people with mild cognitive impairment (MCI) and AD. Individuals diagnosed with AD have 
been shown to have greater apparent brain ageing, observed in several analyses utilising 
the data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).[72, 80, 81] In people 
with MCI, brain-predicted age was a significant predictor of progression to dementia within 
three years from a baseline MRI scan.[80-82] This is important as it demonstrates that brain-
predicted age is sensitive to subtle underlying brain changes that occur prior to outward 
disease manifestation. In a slowly progressing neurodegenerative condition like AD, 
methods for identifying those at greater risk of future decline will be particularly useful. They 
can inform clinical practice and aid in the design of clinical trials of neuroprotective 
therapeutics by stratifying trial enrolment or serving as surrogate outcome measures to 
reduce trial duration making them more feasible.  
Having trisomy 21 (i.e., Down’s syndrome) is another a risk factor for dementia and 
specifically AD. In fact, as many as 80% of people with Down’s syndrome will develop 
dementia,[83] invariably at an earlier age than would be expected in a non-Down’s group 
(i.e., below 65 years of age). During a recent study, I analysed brain-predicted age in adults 
 11 
with Down’s syndrome. The results showed that on average people with Down’s 
syndrome had brains appearing 2.5 years older than their chronological age, which was 
significantly greater than a local healthy control group. This indicates that some changes to 
brain structure in Down’s resemble those seen in normal ageing, but appear at an earlier 
age, akin to the physiological phenotype of the syndrome (e.g., presbyopia, hair loss, 
sarcopenia). Interestingly, when analysing the variability in brain-predicted age in this 
Down’s syndrome group, people who had a greater brain-predicted age difference also 
had higher levels of beta-amyloid deposition (measured using Pittsburgh-compound-B [PiB] 
PET) and were more likely to show signs of cognitive impairment. It seems that in Down’s 
people who exhibited signs of these pathological facets of brain ageing also had older-
appearing brains. This indicates that measures of brain-predicted age are potentially useful 
to characterise individual differences in brain ageing in Down’s, which may in turn help 
better predict subsequent development of dementia. 
Psychiatric disorders have also been investigated using brain-predicted age. In 
schizophrenia, reports indicate that not only is greater brain ageing observed, particularly 
in males,[84, 85] but that this is accelerating over time.[86] In the context of psychosis (e.g., 
bipolar disorder, at-risk mental states), increased brain ageing is less apparent.[84, 85] The 
study by Koutsourleris and colleagues’ also included patients with MDD, finding a mean 
added brain ageing of 4.0 years.[84] People diagnosed with borderline personality disorder 
were also assessed, having a mean added brain ageing of 3.1 years. These studies indicate 
that psychiatric disorders are associated with premature age-related changes to the 
structure of the brain. Nevertheless, further work in larger samples is required to validate 
this. In particular, focus on how brain-predicted age relates to long-term outcomes of 
psychiatric diseases or to treatment response will be especially valuable. 
4.3 Genetic influences on brain-predicted ageing 
Brain-predicted age appears to be heritable,[73] as would be expect given the known 
heritability of brain volumes.[87] This motivates research into candidate genes for the brain-
predicted age phenotype, which may shed light on specific biological pathways implicated 
in brain ageing, in turn presenting possible targets for novel therapeutics aimed at 
maintaining brain health during ageing. Currently, only APOE has been considered. One 
report showed that APOE genotype is associated with increased brain ageing in patients 
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with AD,[81] whereby AD patients carrying the e4 allele showed greater longitudinal changes 
in brain-predicted age compared to AD patients without the e4 allele. This was despite there 
being no cross-sectional differences based on APOE genotype AD patients, people with MCI 
and cognitively-normal controls. Other cross-sectional studies also did not observe effects 
of APOE in people with Down’s syndrome or in the general population.[88, 89] That the 
effects of APOE genotype on brain-predicted age are only detected longitudinally suggests 
the e4 allele may have subtle effects on trajectories of brain health, that only become 
pronounced as disease progression accelerates. Currently, further research is needed in 
order to identify specific genetic factors that influence the brain ageing process. Moving 
beyond APOE to consider other candidates or panels of candidate genes may well prove 
fruitful, if sufficiently large sample sizes can be employed to detect these likely subtle genetic 
effects. 
4.4 Different insults, common consequences? 
The growing body of brain-predicted age neuroimaging research is providing new insights 
into the relationship between brain diseases and the ageing process. It seems that different 
insults to the brain, in the form of trauma, infection or genetic abnormality, can cause 
changes to brain structure that in effect, shift people along the brain ageing trajectory. In 
light of the commonalities in neurobiological and neuroanatomical processes outlined 
above, this apparent added ageing resulting from disease has some face validity. The range 
of brain-age predicted age studies published currently supports the idea that there are 
commonalities between ageing and disease. Potentially, such measures of individual 
differences in brain health could be more relevant for future health outcomes than a specific 
diagnosis is. Although further validation is absolutely necessary, brain ageing findings in 
different diseases support a shift of research emphasis towards clinically-relevant 
neuroimaging measures of individual differences across diagnoses, rather than within. 
5. Focusing on commonalities could lead to a paradigm shift 
As outlined above, the conventional experimental design for neuroimaging research into 
brain diseases is to compare a disease group with a healthy group and establish facets of 
the brain that differ on average. While this approach to comparing and contrasting different 
diseases can provide highly informative, its cogency relies on the validity and relevance of 
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diagnostic groups. Solely relying on measures of central tendency to tell us about diagnostic 
group differences is a reductive strategy and it makes the key assumption of homogeneity 
within experimental groups. However, this assumption is seldom valid. The alternative is to 
not merely focus on where groups differ, but to model where individuals differ. The 
illustration that many of tools we use for measuring aspects of biology provide little or no 
diagnostic specificity and the evidence of commonalities across diagnostic categories 
reinforces the value of considering the individual instead of the group.[90] Furthermore, given 
the similarities between brain diseases and ageing I described earlier, then it is even more 
important to consider the individual in the context of what would be expected given their 
age. To return to the example of hippocampal atrophy, while it is a phenotypic ‘hallmark’ 
of AD,[14, 15] it is commonly observed in MDD, and appears to be a facet of normal ageing. 
Thus, stating that hippocampal atrophy is the result of a disease is imprecise. If AD is 
characterised by a greater degree of hippocampal atrophy than normal ageing, then this 
does become more informative. However, even brief scrutiny of the distributions of 
hippocampal atrophy rates shows that many individuals with a diagnosis of AD have lower 
atrophy rates than the mean in age-matched healthy controls.[91] This begs the question, is 
attempting to characterise the average phenotypes of a disease even the correct approach? 
Perhaps a better focus would be on predicting health outcomes, irrespective of how neatly 
someone fits into a diagnostic category. 
The initial evidence from brain-predicted age neuroimaging studies clearly shows the effects 
are not uniform within disease groups. Interestingly, the variability in disease groups is 
generally similar to that observed in healthy control groups. That makes understanding the 
variability of individual differences in brain ageing of particular interest. As well as being 
related to cognitive performance, this variability also relates to physiological markers of 
ageing and to risk of mortality in older adults.[89] This means that by focusing on what 
measures of individual differences can tell us about a person’s health, we may well be 
better placed to accurately predict what may happen to them in the future. This type of 
paradigm shift, from characterisation to prediction, will be essential if quantitative 
neuroimaging is to have clinical impact. By focusing on predicting prognosis or treatment 
response (or even non-response), we could potentially build powerful statistical models that 
incorporate neuroimaging alongside other sources of data (e.g., genetics, epigenetics, 
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biochemical, physiological) that can make precise medical predictions at a personalised 
level, substantially augmenting current clinical practice for brain diseases and for improving 
brain health during ageing. 
Already, signs of this paradigm shift are appearing. There is a small, but important, body of 
research that is developing sophisticated models of the trajectories of different facets of 
brain ageing, using a range of neuroimaging modalities.[92-96] These models, often using 
longitudinal data, have the potential to map out an individual’s future brain health. These 
anatomical trajectories are of key importance as dramatic changes can occur to the brain 
long before behavioural symptoms appear. By assessing an individual’s personalised brain 
ageing trajectory, in the context of known healthy and degenerative trajectories, we stand 
to be much better informed then by simply knowing their disease diagnosis, particularly if 
they are asymptomatic. Given the overlapping neurobiological, neuroanatomical and 
symptomatic profiles of these diseases with the ageing process, following this approach may 
well shed light on the breadth of different brain diseases and how those diseases relate to 
subtle age-related changes to the brain. 
6. Conclusions and outlook 
Here, I have outlined my view on the neuroimaging literature, concluding that there is 
substantial overlap between different brain diseases and also with ageing. This is supported 
by evidence from behavioural studies and from neurobiological research and indicates that 
the commonalities between ageing and disease have much to tell us about disease 
processes. Moreover, the presence of these ageing and disease commonalities should lead 
us to design better ways to study these phenomena to deliver benefits for patients. The key 
to delivering research that can make clinically useful predictions using neuroimaging is to 
shift away from merely characterising the average difference between a disease group and 
a healthy group. Instead we should consider the individual, attempt to define the status of 
their brain health using multi-modal neuroimaging and then model their personalised future 
trajectory. This should help us better establish if and when they are at risk of suffering from 
cognitive decline, neurodegeneration and manifest brain disease.  
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